



 Cite this: *RSC Adv.*, 2023, **13**, 7153

Bioinks adapted for *in situ* bioprinting scenarios of defect sites: a review

 Ruoqing Li,^a Yeying Zhao,^a Zhiqiang Zheng,^a Yangyang Liu,^a Shurui Song,^a Lei Song,^a Jianan Ren,^{*ab} Jing Dong^{*ac} and Peige Wang  ^{*a}

In situ bioprinting provides a reliable solution to the problem of *in vitro* tissue culture and vascularization by printing tissue directly at the site of injury or defect and maturing the printed tissue using the natural cell microenvironment *in vivo*. As an emerging field, *in situ* bioprinting is based on computer-assisted scanning results of the defect site and is able to print cells directly at this site with biomaterials, bioactive factors, and other materials without the need to transfer prefabricated grafts as with traditional *in vitro* 3D bioprinting methods, and the resulting grafts can accurately adapt to the target defect site. However, one of the important reasons hindering the development of *in situ* bioprinting is the absence of suitable bioinks. In this review, we will summarize bioinks developed in recent years that can adapt to *in situ* printing scenarios at the defect site, considering three aspects: the *in situ* design strategy of bioink, the selection of commonly used biomaterials, and the application of bioprinting to different treatment scenarios.

Received 6th November 2022

Accepted 21st February 2023

DOI: 10.1039/d2ra07037e

rsc.li/rsc-advances

1. Introduction

The repair of tissue and organ defects caused by severe trauma or tumor resection is a major challenge for surgeons worldwide. When tissues and organs are extensively damaged, the existing traditional surgical repair methods include the inability to provide more donor tissues, the possibility of causing additional damage or postoperative infection, and high cost.¹ Therefore, it is expected that 3D bioprinting will eventually replace traditional repair for organ defects. Three-dimensional bioprinting in the modern sense mainly refers to the utilization of cells/cell clusters, bioactive factors and biomaterials as raw materials, which are printed layer by layer by 3D printing to construct bionic tissues or organ transplants with three-dimensional structures and biological functions.^{2–4} However, the irregular shape of many defect sites, the difficulty of perfectly matching the printed graft to the shape of the defect, and the potential for the graft to fail to adjust to the extremely complex and delicate internal environment of the human body after implantation are obstacles to the progress of *in vitro* bioprinting techniques.^{5–7}

On the basis of inkjet bioprinting, Campbell⁸ initially proposed the idea of “*in situ* bioprinting,” which has since

gained much attention in the areas of clinical medicine, regenerative medicine, and tissue engineering. *In situ* bioprinting is based on the scan results of the defect site through computed tomography (CT), magnetic resonance imaging (MRI), or optical scanning. Instead of transferring a prefabricated graft, *in situ* bioprinting can print cells from biological materials or bioactive factors directly on the defect site, and the graft can precisely adapt to the target defect site, further realizing precise control of cell distribution and arrangement in spatial location, organic combination of cells and biological materials, and precise simulation of tissue microenvironment.^{7,9,10} *In situ* bioprinting is mostly intraoperatively performed and is often called intraoperative bioprinting (IOB).^{11,12} IOB refers to a bioprinting process performed on living subjects in a surgical setting, which makes it possible to deliver gene-activated substrates directly to the defect site.^{13,14} Unfortunately, the industry has not clearly defined whether the two are equivalent.

Although promising, *in situ* bioprinting is an emerging field. In addition to the lack of reliable *in situ* bioprinters, another major obstacle to the advancement of this field is the absence of suitable bioinks. Over the last five years, research results on *in situ* bioprinting relevant to various clinical disciplines have emerged, but few articles have detailed the selection of bioinks suitable for different *in situ* printing scenarios. In this review, we discuss bioinks that have emerged in recent years that can be adapted to *in situ* printing scenarios of defect sites, considering the *in situ* design strategies of bioinks, the selection of commonly used biomaterials, and the application of bioprinting to different treatment scenarios.

^aDepartment of Emergency Surgery, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao 266000, China. E-mail: wpgzyz@163.com

^bDepartment of General Surgery, The Affiliated General Hospital of Nanjing Military Region, 305 Zhongshan East Road, Nanjing 210016, China. E-mail: jiananr@njmu.edu.cn

^cSpecial Medicine Department, Medical College, Qingdao University, Qingdao 266071, China. E-mail: dongjing6@hotmail.com



2. *In situ* design strategies for bioinks

2.1 The role of hydrogels in bioinks for *in situ* 3D bioprinting

Bioink is defined as a bioprintable medium that includes biological materials (*e.g.*, alginate and gelatin), cells, and functional factors.^{15,16} These living cells or factors cannot grow without a “biological microenvironment” consisting of sufficient water, oxygen, nutrients, and suitable pH. As a unique “soft material”, hydrogel can meet the needs of this complex microenvironment and is the basis for almost all 3D bioprinting bioinks.^{17,18}

Hydrogels are a class of hydrophilic, three-dimensional network structured substances that swell rapidly in water without dissolving and have good biocompatibility and water retention, so they have attracted widespread attention in the past decade.^{19–21} Because of their structural similarity to the extracellular matrix (ECM), hydrogels have been widely studied and applied in biomedical fields, including tissue engineering and drug delivery.^{22–26} Three-dimensional bioprinting technology enables high-precision and rapid printing using bioinks prepared from hydrogels for regeneration and repair of various tissues and organs. The selection of hydrogels should take into account cell construction, proliferation, long-term survival, mechanical strength, porosity, degradability, biocompatibility,

and print suitability.^{27–29} In addition, attention needs to be paid to the interaction of bioinks with key cells, including cell settlement in the cartridge, cell viability during extrusion, and cell viability after ink curing.^{30–32}

2.2 Design considerations of bioinks for *in situ* 3D bioprinting

With *in situ* printing, bioink can be directly deposited into organ defects, which enables *in situ* bioprinting to have the advantages of avoiding defects during transplantation and reducing the treatment time and pain of patients compared with *in vitro* bioprinting and transplantation. It is important to stress that the following points need to be fully considered at the design stage of bioink^{33–37} (Fig. 1). (i) Good biocompatibility is essential for the application of biomaterials *in vivo*, so bioink must be non-toxic and non-immunogenic. (ii) Rapid crosslinking is necessary for *in situ* bioprinting due to the inevitable movement of patients during clinical operations. (iii) When a certain link in the microenvironment fluctuates, it will affect the concentration of the bioink and the crosslinking concentration of the reagent at the printing site. Therefore, non-chemical crosslinking, especially light-crosslinking and thermal crosslinking, which do not cause secondary toxicity, are the main crosslinking methods for *in situ* 3D bioprinting bioinks. (iv) Unlike the temperature-controlled receiving substrates



Fig. 1 Design points and applicable scenarios for bioinks *in situ* 3D bioprinting.



on *in vitro* bioprinters, *in situ* bioprinting has a specific receiving substrate whose temperature is usually fixed around body temperature (37 °C), so the rheological properties of bioinks cannot be controlled by changing the temperature, which may affect the thermal curing of heat-sensitive bioinks and ultimately affect the print quality. (v) The cross-linked bioink should have a low mechanical modulus to encapsulate cells to exert a therapeutic effect, but this contradicts the high mechanical properties of the bioink structure required for the defect site. This paradox can be resolved by building a composite structure that prints a strong scaffold with a soft hydrogel inside. (vi) Support structures cannot always be used for *in situ* bioprinting, which requires the bioinks to have high fidelity and structural stability. (vii) The *in situ* bioink is preferably portable, providing fast and effective assistance for rescue in emergencies such as wars, disasters, and acute trauma.

To avoid infection during clinical use, bioink must be sterilized prior to handling and binding to cellular components.^{38,39} It should be noted that sterilization methods can adversely affect bioink. For example, the free radicals produced by radiation sterilization and ultraviolet sterilization can affect the hydrodynamics and shapeability of bioinks and, in turn, damage the microstructure of bioinks. High-energy water vapor generated by high-pressure steam sterilization and free radicals generated by radiation sterilization and ultraviolet sterilization can cause the loss of activity of biological macromolecules such as proteins and enzymes and destroy the activity of biological macromolecules contained in bioinks. Residues from ethylene oxide sterilization are carcinogenic and affect the survival of encapsulated cells in bioinks, so the use of this sterilization method should be reduced for cell-loaded bioinks.⁴⁰ In conclusion, we strongly urge that when selecting materials for *in situ* 3D printing bioink, much attention should be paid to the potential effects of different sterilization methods on the selected materials in clinical scenarios.

In addition, the requirements for bioink imposed by different forms of printing technology are quite different, so the design of bioink is also closely related to the printing process selected. At present, the printing methods mainly used for *in situ* 3D bioprinting are droplet/inkjet-based bioprinting and extrusion-based bioprinting. Droplet/inkjet-based bioprinting, which involves thermally or acoustically spraying a bioink onto a tissue defect to construct a graft, requires the bioink to be in a liquid state and have an appropriate viscosity to be ejected from a nozzle orifice. At the same time, the method can print on a non-horizontal surface, which is of great significance for applying the *in situ* 3D biological printing technology to repair complex tissue damage.^{7,41} Extrusion-based bioprinting technology continuously extrudes bioink from a nozzle using a pneumatic or mechanical extrusion system and prints it into a designed three-dimensional structure. However, the interference of various enzymes and ions at the defect site may affect the cross-linking process of the bioink, leading to premature cross-linking or nozzle tip blockage.^{6,42}

Laser-assisted bioprinting and reduction polymerization-based bioprinting are also beginning to emerge in *in situ*

printing. Laser-assisted bioprinting uses a high-energy laser pulse to produce high-pressure bubbles in a thin layer of bioink that are then ejected to specified locations. In the sterile environment of the operating room, doctors can guide the fully automatic robot printer to realize micrometer to millimeter cell implantation, and the bioink can print to the defect site more accurately.⁴³ Bioprinting based on reduction polymerization involves selectively crosslinking a photocurable polymer solution loaded with cells using a light source, which has the advantages of high printing speed and high resolution. When applied to *in situ* printing, stronger penetration of ultraviolet and visible light is required to achieve curing of the printed structure deep in the tissue.^{44–46} However, these two printing methods expose cells to ultraviolet light during the printing process, which is harmful to the encapsulated cells.^{47,48} Therefore, how to achieve *in situ* UV-curing of bioink on the premise of protecting cells from damage is a problem that we should think about in the design stage.

3. Materials available for *in situ* 3D bioprinting

Different bioinks can induce different degrees of cell responses. Alginate, collagen, gelatin, hyaluronic acid, silk fibroin, chitosan, and peptides are the seven most commonly used materials for *in situ* bioprinting. Here, we will introduce these common materials in detail, and show some representative research results (Table 1).

3.1 Alginate

Alginate is a biocompatible anionic polymer derived from brown algae.⁴⁹ It has been used in a variety of biomedical scenarios, such as promoting wound healing, drug delivery, and tissue engineering. Because of its low viscosity and zero shear viscosity, pure alginate has a poor ability to maintain its shape. Alginate oxidized by periodate is easy to hydrolyze.⁵⁰ To overcome such common obstacles, alginate is often modified or blended with other materials to optimize its performance for *in situ* 3D printing.

For example, Kim⁵¹ presented 3D bioprinting with tunable gelation kinetics by controlling the covalent crosslinking density and gelation time of a tyramine-functionalized alginate hydrogel (ALG-TYR) *via* enzymatic reactions with horseradish peroxidase and hydrogen peroxide. Then Kim introduced collagen into the ALG-TYR hydrogel network to increase the mechanical modulus and cytocompatibility. Finally, Kim printed a vascular ECM-mimicking scaffold with this hybrid hydrogel and demonstrated that the scaffold was capable of supporting tissue growth for clinical translation in regenerative and personalized medicine. In a seminal work, Cao *et al.*⁵² applied visible light-cured methacrylate alginate bioink to 3D-bioprinted cell-loaded biofilms. The researchers prepared sodium alginate structures with high structural accuracy using a direct-writing printer and immersed them in Ca²⁺ solution and chitosan solution, respectively, to achieve double contraction and deformation of the sodium alginate hydrogel structure.



Table 1 Examples of various bioinks suitable for *in situ* bioprinting^a

Biomaterial	Crosslinking mode	Active ingredient/animal model	Result
Phenyl propionic acid-conjugated gelatin (GHPA)/graphene oxide (GO) ⁶⁴	Dual enzyme-mediated cross-linking reaction	C2C12 myoblasts	Provides a cell-suitable cellular microenvironment that supports adhesion, spreading, and growth. And promotes the myogenic differentiation of C2C12 cells
Collagen type I (COL)/agarose (AG)/sodium alginate (SA) ⁵⁸	—	Chondrocytes	Suppresses dedifferentiation of chondrocytes and preserves the phenotype. And promotes proliferation and survival of chondrocytes
GelMA/hyaluronic acid ⁷⁶	—	hADSCs/Articular cartilage regeneration and repair model	High biocompatibility and adequate mechanical strength that can facilitate the regeneration and repair of articular cartilage
Catechol-functionalized, gelatin methacrylate (GelMA/C) ⁷⁷	Oxidative crosslinking	HCASMCs/bioprinted vascular construct model	Improves vascular remodeling of both smooth muscle and endothelium
Tyramine-functionalized/alginate hydrogel (ALG-TYR)/collagen (COL) ⁵¹	Enzymatic crosslinking and thermo-responsive crosslinking	—	Printable, retains high fidelity after printing, and has high cell survivability
Methacrylate alginate/Ca ²⁺ /chitosan ⁵²	—	—	Achieves double contraction and deformation of the sodium alginate hydrogel structure
Microalgae/alginate/GelMA ⁵⁴	—	Oxygenic photosynthesis unicellular microalga (chlorella pyrenoidosa)/the diabetic chronic wounds	Accelerates wound healing
Thiol-modified hyaluronic acid (HA-S)/polyethylene glycol diacrylate (PEGDA) ⁸⁰	Michael-type nucleophilic addition reaction and a prolonged maturation of disulfide crosslinks	—	Has tunable mechanical and bio-adhesive ligand properties
Chitosan (CH)/oxidized hyaluronic acid (HAD) ⁸¹	Schiff base reaction	—	Maintains cellular phenotypic integrity and promotes extracellular matrix production
Chitosan/2-hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone/fish skin collagen ⁹²	Thermo/photo dual cure crosslinks	—	Has tunable mechanical properties, proper microstructure, and biodegradability for 3D cell culture, and improves cytocompatibility
The newly designed peptide sequences Ac-Ile-Val-Phe-Lys-NH ₂ (IVFK) and Ac-Ile-Val-Cha-Lys-NH ₂ (IVZK) ⁹⁶	Self-assembly	—	The hydrogel proves to be durable, easily printable and offers excellent biocompatibility

^a “—” indicates that this part cannot be found in the article.

With the continuous soaking of sodium alginate structures in both solutions, the mechanical properties of sodium alginate hydrogels were continuously enhanced. Hakimi *et al.*⁵³ proposed a handheld skin printer, and consistent sheet formation was achieved by coordinating the flow rates at which bioink and cross-linker solution were delivered with the speed at which a pair of rollers actively translated the cartridge along the surface. This printer enables the *in situ* formation of biomaterial and skin tissue sheets of different homogeneous and architected compositions, so it can be used for wound healing *in situ*.

To overcome the non-biological activity, uncontrollable biodegradability, and unstable structural/mechanical stability of alginate, various advanced strategies have been proposed in recent years, either relying on reformulation of bioink formulations (*e.g.*, physical mixing and chemical modification) or

relying on innovations of bioprocessing processes (*e.g.*, aerosol-assisted, microgel bioink, collaborative printing, micro/nanoscale printing, and 4D bioprinting), allowing alginate-based bioink applications to expand widely.

Besides, Wang *et al.*⁵⁴ inspired by the natural symbiotic relationship between salamanders and algae, presented novel living photosynthetic scaffolds using an *in situ* microfluidic-assisted 3D bioprinting strategy for adapting irregular-shaped wounds and promoting their healing. Photosynthetically viable unicellular microalgae were introduced directly during 3D printing, and the generated scaffolds could produce sustainable oxygen under light. Thus, the scaffolds could significantly accelerate the chronic wound closure by alleviating local hypoxia and increasing angiogenesis and ECM synthesis. These results indicate that the *in situ* bioprinting of living photosynthetic microalgae offers an effective autotrophic



biosystem for promoting wound healing, suggesting a promising therapeutic strategy for diverse tissue engineering applications.

3.2 Collagen

Collagen is a major component of the ECM in the skin and accounts for approximately 30% of the total protein in mammals.^{55,56} It consists of different numbers of triple helices and different α polypeptide chains, which can form 28 different cell-binding sequences. As the most common protein in mammals, collagen does not elicit significant immune responses and can promote cell adhesion and growth.³⁵ However, the immunogenicity of collagen is susceptible to other proteins, cross-linking reagents, and residual cells, and may also contribute to inflammation and disease transmission.⁵⁷ In addition, the mechanical properties of collagen at physiological temperature are unstable and its gelation rate is slow, which limits its application scope as a bioink when used alone. Therefore, collagen is often combined with other biomaterials to create bioinks with improved structural integrity, printability, and bioactivity.

A significant number of studies have begun to focus on optimizing collagen as part of a multi-component bioink and applying it to 3D bioprinting. Yang *et al.*,⁵⁸ for example, used collagen type I or agarose mixed with sodium alginate to serve as 3D bioprinting bioinks and incorporated chondrocytes to construct *in vitro* 3D-printed cartilage tissue. This approach improved the printed tissue's mechanical strength and effectively inhibited chondrocyte dedifferentiation. Moreover, the combination of collagen type I and sodium alginate effectively suppressed the dedifferentiation of chondrocytes and preserved the phenotype, so this combination integrated good mechanical properties with biological properties. Similarly, a study by Liu *et al.*⁵⁹ demonstrated the applicability of collagen–alginate composite bioink in cartilage bioprinting, showing that printed collagen–alginate saline gels could support sustained drug release from incorporated poly(ϵ -caprolactone) microspheres. Heidenreich⁶⁰ investigated the rheological properties of collagen–chitosan composite bioink with different components and showed that it had stable mechanical properties and almost negligible cytotoxic effects on NIH-3T3 fibroblasts. Hence, this bioink should be suitable for *in situ* bioprinting.

3.3 Gelatin

Gelatin is a natural polymer produced by hydrolysis of collagen,⁶¹ which can be formed after cooling at low temperatures (20–30 °C). Gelatin possesses thermosensitive properties that allow its molecular bonds to be easily destroyed by high temperatures, enabling printing and stacking in a temperature-controlled manner.⁶² For example, the rapid gelation of gelatin at moderate temperatures allows the printed structure to have strong initial stability even when other unstable materials are added.⁶³ Due to their thermosensitive qualities, biocompatibility, and other benefits, gelatin and its derivatives have generally become more popular natural bioinks. These materials hold significant promise as candidates for *in situ* 3D

printing bioinks and have strong potential as candidates for *in situ* 3D printing bioinks. Gelatin as a type of bioink has good biocompatibility, solubility, and degradability.⁶⁴ Gelatin-based bioink viscosity can be easily altered by adjusting the temperature or increasing the concentration of gelatin in bioink. In addition, gelatin has several side chains that allow it to be chemically cross-linked and modified and enable it to be successfully applied to *in situ* 3D printing. To more accurately replicate the ECM and simulate its intrinsic characteristics in loaded cells, Kang *et al.*⁶⁴ used 3D-printed bioink composed of phenol-rich gelatin and graphene oxide as a component of myogenic-inducing materials to form a hydrogel network *in situ* through a double-enzyme-mediated cross-linking reaction to provide an appropriate cellular microenvironment and promote myogenic differentiation of C2C12 skeletal myoblasts, which showed good application prospects in tissue engineering and regenerative medicine.

Gelatin in the form of methacryloylated gelatin (GelMA) is widely used in tissue engineering, particularly in the generation of bone, cartilage, skin, and vascular networks.^{65,66} GelMA is a modified gel with photosensitive functional groups introduced into the gelatin side chain,^{67,68} which retains the good biocompatibility and degradation properties of gelatin, forms covalent cross-linked hydrogels with good thermal stability under the action of UV light and photo-initiators, and shows good printing adaptability and biocompatibility in the field of 3D bioprinting.^{69,70} However, it is difficult to form biological scaffolds by extrusion 3D printing due to the poor mechanical properties and structural maintenance of GelMA crosslinked by light. In addition, GelMA hydrogel is beneficial for cell adhesion and remodeling because of its arginine–glycine–aspartate (RGD) peptide sequence and matrix metalloproteinase (MMP) sequence.⁷¹ It should be noted that the porosity of GelMA hydrogels plays an important role in the transport of oxygen and nutrients required for cell growth.⁷² Studies have shown that GelMA hydrogels with relatively low concentrations (*i.e.*, $\leq 5\%$ w/v) are more conducive to cell growth,^{73,74} but the decrease of concentration will lead to the decrease in the compression modulus, which deteriorates the mechanical properties of GelMA hydrogel.⁷⁵ High-concentration gels have good shear-thinning behavior and high mechanical properties, but often smaller pore size and lower swelling rate, which is detrimental to the diffusion of nutrients and oxygen needed for cell survival. Therefore, it is important to find a balance between supporting cell growth and obtaining adequate mechanical properties. The preparation of GelMA-related bioinks with appropriate pore size, biological properties, and mechanical properties that are suitable for various tissue engineering is a difficult challenge, and it seems to be a good option to overcome these problems by adjusting gel concentration or by mixing with other components.

Duchi *et al.*⁷⁶ described an *in situ* approach that allows 3D bioprinting of human adipose-derived stem cells laden in 10% GelMA/2% HAMA hydrogel. They used coaxial extrusion to obtain a core/shell bioscaffold with high cell viability and adequate mechanical properties for articular cartilage regeneration and repair. Cui⁷⁷ developed a catechol-functionalized



gelatin methacrylate that undergoes rapid oxidative cross-linking *in situ* to form an elastic hydrogel, which can be engineered with controllable mechanical strength, high cell/tissue adhesion, and excellent bio-functionalization. At the same time, they also demonstrated that *in situ* bioprinted vascular structures have appropriate biomechanical properties, higher tissue affinity, excellent perfusion, and permeability, and show significant potential in creating biomimetic, functional vascular systems.

3.4 Hyaluronic acid

Hyaluronic acid is present in the ECM and is abundant in the skin, connective tissues, and eyes, and it has good biocompatibility, biodegradability, and bioabsorbability.^{78,79} However, due to its high water solubility and low stability, hyaluronic acid is not suitable as a stand-alone bioink because of its lack of robustness as a supporting structure. These shortcomings need to be addressed by crosslinking hyaluronic acid or combining it with other components.

Our ideal bioink should have suitable properties that facilitate scaffold expansion, differentiation, and remodeling into suitable tissue, and pay more attention to the firmness of the gel and scaffold binding site and allow cells to attach to this scaffold. For example, Godesky⁸⁰ investigated a hydrogel system based on thiol-modified hyaluronic acid and polyethylene glycol diacrylate. This gel scaffold can form appropriate support structures, has adjustable mechanical properties, and has good bioadhesive ligand properties to support the growth of tissue cells.

Thomas *et al.*⁸¹ aimed to study the effects of the stiffness composition of a two-component injectable hydrogel based on chitosan and oxidized hyaluronic acid on the growth and functionality of encapsulated chondrocytes. Gel stiffness was found to have a great impact on the chondrocyte microenvironment, such as maintaining cell phenotypic integrity and promoting ECM production. This study is of great reference value for the practical application of biomaterials.

At present, research designs for *in situ* printed bioinks based on hyaluronic acid are still lacking. However, with *in situ* printing as an emerging field and hyaluronic acid as a candidate bioprinting ink, their combination may hold unexpected potential.

3.5 Silk fibroin

Silk fibroin from *Bombyx mori* is easy to process, abundant in sources, and can form strong materials through physicochemical reactions, which have certain textile properties, biodegradability, cytocompatibility, and other valuable characteristics.^{82,83} By adjusting the β -sheet content, cross-linking degree and morphological structure of silk fibroin bioink, its mechanical properties and its degradation rate *in vivo* can be adjusted.^{84,85} In addition, silk fibroin may help to avoid cell-specific effects in some cases because silk fibroin lacks the RGD sequence as a cell adhesion epitope, making it a viable option for quality bioinks.⁸⁶ It has been shown that the structure and function of cartilage pairing can be optimized by

integrating fibroin with gelatin loaded growth factors into bioink for 3D printing.^{83,87} Silk fibroin and glycidyl methacrylate can be mixed to form a bioink that has excellent mechanical and rheological properties, and is suitable for constructing blood vessels in the hydrogel state. This provides many possibilities for the remodeling of tissue structures such as blood vessels and highly complex organ structures such as the brain.⁸⁸

Compared with ordinary 3D printing, *in situ* printing can more ideally adapt to target defects and promote tissue repair and regeneration. McGill *et al.*⁸⁶ created a method for using silk fibroin bioink to make constructs composed of bioink with encapsulated cell function, and they applied this method to manufacturing patient-specific memory-shaped implants. In addition, they demonstrated the attachment of peptides to silk fibroin hydrogels through crosslinking of tyrosine with horseradish peroxidase and hydrogen peroxide. This cross-linking mechanism has non-negligible potential for extrusion 3D printing in the clinical setting because it is capable of extracting patient-specific anatomical data and designing corresponding shape memory implants.

In summary, as a bioink that can be used for *in situ* printing, silk fibroin should be designed and processed comprehensively, especially in terms of viscosity, rheology, encapsulation, and biocompatibility. The performance of silk fibroin bioinks for *in situ* printing can be improved by changing the concentration of fibroin solutions or incorporating other biopolymers to compensate for the limitations of individual components.

3.6 Chitosan

Chitosan is a product of the deacetylation of chitin and contains $-NH_2$ and $-OH$ active moieties that can be easily combined with other polymers. The special molecular structure and physicochemical properties of chitosan cause it to have good biocompatibility, biodegradability, adhesion, and antibacterial and anti-inflammatory properties.^{89,90} In addition, chitosan can be slowly degraded by lysozyme *in vivo* to form monosaccharides or oligosaccharides that can be absorbed by the human body, and its degradation performance, mechanical properties, and biological properties can be improved by modification or the addition of components.⁹¹ Therefore, chitosan has been widely used in medical tissue engineering as a natural biomaterial.

Bioinks for *in situ* printing should have the advantages of rapid solidification in addition to good mechanical properties, degradability, and other essential properties. Therefore, Liu *et al.*⁹² proposed a facile design for a thermo/photo dual-cure composite hydrogel made of methacrylated HBC (MHBC) and soluble collagen. The composite hydrogel exhibited rapid thermally induced sol-gel transition and contraction, adjustable mechanical properties, appropriate microarchitecture, biodegradability suitable for 3D cell culture, and improved cytocompatibility by modulating the methacrylation and chitosan/collagen (M/C) ratio of MHBC. Both desirable printability and cytocompatibility enable the M/C composite hydrogel to be a potential candidate as a bioink for *in situ* 3D bioprinting.

Puertas-Bartolomé *et al.*⁹³ presented a novel bio-printing methodology based on a dual-syringe system with a static



mixing tool that allows *in situ* crosslinking of a two-component hydrogel-based ink in the presence of living cells. The reactive hydrogel system consists of carboxymethyl chitosan and partially oxidized hyaluronic acid that undergo fast self-covalent crosslinking *via* Schiff base formation. This allows better structural integrity, precise adaptation to the defect site, and promotion of soft tissue regeneration.

On the premise of ensuring rapid curing, all the above-mentioned studies minimize damage to the organism caused by UV light curing or chemical cross-linker curing, and the effect on the tissue structure is almost negligible. From these studies, we can see that chitosan has a bright application prospect as a bioink for *in situ* printing, but it is often necessary to enhance the mechanical strength of chitosan by combining it with additional components.

3.7 Peptides

Peptides, compounds with two or more amino acids connected by peptide bonds, are intermediate substances between amino acids and proteins. Each peptide has a unique composition structure, and the structure of a peptide determines its function. Peptides were discovered in 1990 when a self-assembled peptide as a repeat fragment was found in yeast protein.⁹⁴ Ultrashort amphiphilic peptides form β -fibrils through α -helical intermediates,⁹⁵ which have been shown to self-assemble into nanofibrous hydrogels that resemble native ECMs, provide an environment conducive to cell survival and maintain the basic physiological functions of cells. In addition, the self-assembly of peptides can be modulated by adjusting their internal factors (*e.g.*, amino acid sequence, repeat unit number of assembled motifs, and peptide concentration) and external stimuli (*e.g.*, temperature, pH, and salt concentration) to exhibit stimulus-responsive properties and adjustable mechanical properties.^{96,97} Another advantage of self-assembled peptides is their inherent biocompatibility and biodegradability, which enable them to stimulate the extracellular environment, support cell growth, and be used in biomedical research *in vitro* and *in vivo*, heralding their good application prospects as bioinks.^{98–100} Moreover, their short length and ease of functionalization are conducive to synthesis and customization.

Currently, there are research teams working to explore self-assembled peptide bioinks for *in situ* 3D printing. For example, Rauf *et al.*¹⁰¹ reported a unique *in situ* 3D bioprinting method. In their research, two novel ultra-short tetramer peptides, AC-Ile-Val-Cha-lys-NH₂ (IVZK) and AC-Ile-Val-Ph-lys-NH₂ (IVFK), were developed at ambient temperature. Their results demonstrate that the finished structures are highly durable and biocompatible when printed using the newly developed peptides IVZK and IVFK as bioinks. This shows the great potential of ultra-short tetramer peptides as bioinks for *in situ* printing. In all, self-assembled peptides have the advantages of excellent biomimicry, stimulus responsiveness, biocompatibility, biodegradability, ease of synthesis, and functionalization, which makes them ideal choices for bioinks. The application of self-assembled peptides to bioprinting can reproduce the dynamic complexity of biological tissues, thereby

advancing the biomedical applications of current peptide hydrogel scaffolds.¹⁰²

4. *In situ* 3D bioprinting in different printing scenarios

In situ 3D bioprinting adds many demanding requirements compared with conventional 3D bioprinting because of the changing application scenarios. First, the *in situ* printing environment could be a battlefield, disaster relief scenario, or other unpredictable environment, which requires bioink to have rheological stability, meaning the printing performance will be unaffected if the printing environment changes drastically from low to high temperature. Second, bioinks should be able to keep the printed structure from collapsing under high body temperature and blood-filled infiltration environment and enable the printed cells to survive efficiently and quickly functionalize to start the damage repair as soon as possible. In addition, the printed structures need to adhere to the defective tissues strongly enough so that they will not detach from the defect during *in vivo* repair and cause secondary damage. Finally, the rapid functionalization of printed tissues and the portability for acute treatment are urgent issues that need to be addressed.³⁴

Different printing scenarios have different needs for bioinks. For scenarios such as printing tissues or organs, bioinks need to meet the anatomical structure and physiological needs of the site;¹⁰³ for scenarios such as specific external environments, the functionalization of bioinks becomes more important. Hence, the following section will introduce the latest advances in *in situ* 3D bioprinting in several specific scenarios common in clinical settings.

4.1 Bone/cartilage defects

Bone/cartilage grafts are mainly limited due to their scarcity, donor site complications of autologous transplantation, and immune rejection of allogeneic transplantation, so there are still many challenges in clinical treatment. However, natural bone/cartilage is structurally and functionally heterogeneous and anisotropic, and different regions have unique material composition and mechanical and biological properties, so current tissue engineering strategies cannot perfectly reconstruct the anatomy of natural osteochondral tissue.¹⁰⁴ As an emerging tissue engineering technology, *in situ* 3D bioprinting technology creates highly ordered complex structures out of bioactive materials and implants them into host tissues for repair, which can be used as an alternative to bone/cartilage transplantation.¹⁰⁵

4.1.1 Bone defects. Bone regeneration is highly dependent on an adequate vascular system, and early neovascularization after stent implantation promotes cell proliferation and tissue ingrowth, followed by bone mineralization and regeneration, while scanty vascular infiltration and hypoxia often lead to central necrosis of the graft or show fibrous encapsulated osseointegration failure.^{106–108} The microenvironment of interaction between vascular endothelial cells and bone formation-



related cells may play an important role in vascularized bone regeneration. Prevascularization, multi-layer biomimetics, and loading bioactive components can be used to improve the biological activity of the scaffold, counteract the inertia possessed by synthetic polymers, and create a microenvironment to recruit and regulate local stem cells so as to achieve *in situ* vascularized bone regeneration and improve the bone integration ability of the graft.

Keriquel *et al.*^{43,109} used a laser-assisted bioprinting system to repair mouse calvaria defects in a minimally invasive manner by *in situ* printing of nano-hydroxyapatite lasers. Subsequently, the group used mesenchymal stem cells, nanohydroxyapatite, and type I collagen as bioinks in the repair of critical-sized cranial defects in mice and successfully induced *in situ* hemodynamic reconstruction and subsequent tissue regeneration of the bone defects.¹¹⁰ Vidal *et al.*¹¹¹ used biphasic calcium phosphate to repair 15 mm critical-sized rabbit ulnar defects by *in situ* printing of prevascularized synthetic bone grafts, and micro-CT and histological examination showed that the bone regeneration rate of prevascularized synthetic bone grafts was significantly higher than that of nonvascularized artificial bone after 8 weeks.

In a recent study, Xie *et al.*³⁴ proposed a novel idea of “bio-concrete” ink, in which pre-functionalized cell-laden microspheres were used as “stones” and highly concentrated GelMA hydrogel pre-polymerization solution was used as “cement”. (Fig. 2). Moreover, they developed a robotic *in situ* 3D bioprinting system to achieve *in situ* repair of irregular wounds. They believe the advantage of *in situ* printing with bioconcrete bioink is its 100% biological components, which can promote the self-repair of skull defects at the histological level, rather than simply repairing the skull with prostheses.

In addition, the multilayer bionic scaffold exhibited good osteo-inductive activity and facilitated cell survival in the scaffold, making it a promising scaffold biomaterial for clinical applications. Zhang *et al.*¹¹² used low-temperature *in situ* 3D bioprinting to construct a novel bioactive poly (lactic-co-glycolic acid)/ β -tricalcium phosphate composite scaffold loaded with graphene oxide and bone morphogenetic protein-2-like peptide to repair critical-size bone defects. *In vitro* experiments and *in vivo* animal experiments have shown that hierarchical porous structural interfaces are important regulators of cellular activity and differentiation. However, there are still many bone tissue injuries with multiple pathological changes in clinical practice,



Fig. 2 Train of thought of A–C bioink designing and sketch of the preparing/using method.³⁴ Reproduced from ref. 34 with permission from the Springer Nature Limited, Copyright© 2023.



which require stents loaded with therapeutic drugs. Feng *et al.*¹¹³ developed a unique cell-infiltrating and injectable gelatin hydrogel that effectively prevented bone mineral density reduction and promoted bone formation in an animal model of steroid-related osteonecrosis in mice by *in situ* injection of an injectable hydrogel encapsulating bone marrow mesenchymal stem cells and icaritin. This study demonstrates the feasibility of using injectable hydrogels as therapeutic drug carriers and provides a new direction for subsequent clinical applications.

4.1.2 Cartilage defects. Cartilage damage due to osteoarthritis, aging, and joint trauma is a major cause of joint pain and chronic disability.^{114–116} Compared with bone tissue, cartilage injuries often require more complex properties of repair materials due to the lack of vascular, nerve, and lymphatic supply. Articular cartilage is composed of three anatomical regions, namely superficial cartilage, middle cartilage and deep cartilage. Existing clinical repair and tissue engineering techniques are less able to reconstruct such complex microstructures, and the inability of the regenerated tissue to restore the orderly arrangement of cells and outer matrix in healthy tissue is one of the reasons for the failure of current osteochondral treatment strategies.¹¹⁷ Three-dimensional bioprinting can accurately deposit bioactive substances such as cells, biomaterials, and growth factors, so it can reconstruct cartilage tissue with layered structures.^{35,118}

An important challenge of *in situ* 3D bioprinting technology is to maintain the viability of living cells, the sensitivity of growth factors, and the activity of bioactive substances. Recently, a handheld bioink extrusion device was developed for cartilage repair. O'Connell *et al.*¹¹⁹ developed a handheld bioprinting device called “Biopen” to manually control the deposition of GelMA/methacrylate-hyaluronic acid hydrogels and repair cartilage defects *in situ* by UV cross-linking. *In vitro* studies have shown that human adipose-derived stem cells remain highly active in hydrogels one week after printing.⁴⁷ Subsequently, the research group used this device to conduct sheep animal experiments, and the results showed that at 8 weeks after *in situ* printing, the scaffolds showed good cartilage regeneration effects at both the macroscopic shape and microscopic protein gene levels.^{120–122}

A 3D-bioprinted difunctional scaffold based on aptamer HM69-mediated mesenchymal stem cell-specific recruitment and factor-enhanced cell chondrogenesis developed in a recent study may be a promising strategy for articular cartilage regeneration *in situ*.¹²³ In this study, aptamers that could specifically recognize and recruit autologous mesenchymal stem cells were chemically conjugated to the ECM of acellular cartilage and then mixed with GelMA to form a photocrosslinkable bioink for 3D bioprinting, and the biodegradable polymer poly(ϵ -caprolactone) was selected to provide mechanical strength for 3D bioprinted constructs. This bifunctional scaffold provides a favorable microenvironment for cell adhesion and proliferation and promotes chondrogenesis, thus greatly improving cartilage repair in rabbit full-thickness defects. Chen *et al.*⁴⁴ used digital near-infrared photopolymerization printing technology to non-invasively print subcutaneous bioink into customized tissue structures *in situ* by

in vitro irradiation with near-infrared light. In further experiments, the researchers printed auricular structures containing chondrocytes non-invasively and subcutaneously in mice based on digital near-infrared photopolymerization. The scaffolds maintained good cosmetic structure after one month, and type II collagen secretion by chondrocytes was observed.

4.2 Skin defects

The normal wound healing process is very precise and includes a series of processes including hemostasis, inflammation, proliferation, and ECM remodeling. In pathophysiological conditions such as trauma, burns, and chronic wounds (*e.g.*, wounds resulting from diabetes and pressure ulcers), this normal healing process can be severely dysregulated, resulting in the loss of most skin tissue and failure to heal.^{124,125} Traditional repair methods, such as autologous skin grafting, have poor timeliness of treatment due to limited skin sources and long preparation times. By contrast, *in situ* skin bioprinting is an on-site printing strategy that scans wound morphological characteristics after debridement and directly deposits cells and biomaterials on the defect,^{11,126,127} which can solve the problem of poor timeliness.

Bioinks, as delivery media for encapsulated cells, need to provide a microenvironment for the maturation of skin bioprinting in addition to minimizing cell damage during the printing process.¹²⁸ Alongside the biomechanical and structural characteristics of the skin, shape fidelity and printing resolution should also be taken into account. Bioinks need to be easily printed with good resolution and able to maintain their structure to accommodate the skin maturation process after printing. Another important factor to consider is the rate at which materials degrade *in vivo*; scaffolds should degrade at rates that match ECM production and remodeling activities.^{129,130}

As the largest and most superficial organ of the human body, the skin is the most suitable organ for *in situ* bioprinting therapy. Many *in situ* bioprinting studies have focused on repairing skin defects, and some progress has been made in animal experiments.^{53,131} Zhao *et al.*¹³² integrated platelet-rich plasma (PRP) at a concentration of 5% into an alginate-gelatin (AG) composite hydrogel for *in situ* extrusion bioprinting of full-thickness rat skin defects and found that the addition of PRP improved the cellular behavior of seed cells, regulated the tube formation and macrophage polarization of vascular endothelial cells in a paracrine manner, accelerated high-quality wound closure, regulated inflammation and initiated angiogenesis compared with AG bioink alone (Fig. 3).

4.3 Other defects

To meet the demand of minimally invasive and precise treatment in clinical practice, 3D bioprinting is being transformed from *in vitro* printing to non-invasive *in situ* printing and other forms of *in vivo* printing. Zhao *et al.*¹³³ developed a miniature bioprinting platform that can be installed on endoscopes. This printing platform has Delta robots that can be miniaturized in combination with microelectromechanical systems, so it has





Fig. 3 (A) Schematic illustration of bioprinting process using PRP containing multi-component bioink. (B) Immunohistochemical staining of iNOS and ARG-1 to determine the polarization of macrophages on day 3. Scale bar: 50 μm . (C) Evaluation of *in vivo* angiogenesis in the *in situ* bioprinted constructs on day 7. Immunofluorescent staining of CD31 and α -SMA for mature blood vessels. Scale bar: 50 μm .¹³² Reproduced from ref. 132 with permission from the Elsevier, Copyright© 2022.

the advantages of reducing *in vivo* invasiveness, small size, and fast response speed. The printing platform enters the human body through the endoscope and performs tissue repair after reaching the injury site, realizing *in situ* printing in the body. To simulate the anatomical structure of the stomach, the team used a gelatin–alginate hydrogel with human gastric epithelial

cells and human gastric smooth muscle cells as bioink to print a layered tissue scaffold in a stomach model (Fig. 4). Follow-up cell culture results showed that the printed cells maintained a high survival rate and stable proliferation ability in the tissue scaffold, which indicated that the cells in the printed tissue scaffold had good biological functions. Gastric wall injury is



Fig. 4 (i) Schematic of *in situ in vivo* bioprinting taking the case of treatment for gastric wall injuries. (ii) Bioprinting experiment equipment. (A) Bioprinting platform installed to a curved pipe mimicked an endoscope to process bioprinting inside a model of stomach. (B) The process of *in situ in vivo* bioprinting. (C) The printed 2-layer tissue scaffolds consisting of GES-1 cells and HGSMCs before cross-linking. (Scale bar: 1 cm). (D and E) The printed 8-layer scaffold with favorable mechanical properties.¹³³ Reproduced from ref. 133 with permission from the IOP Publishing Ltd, Copyright© 2020.



a common gastrointestinal problem, and about 12% of the world's population suffers from varying degrees of injury. If left untreated, open wounds in the stomach wall can lead to serious consequences, even requiring surgical intervention. Therefore, this work has been called an innovative advance in the fields of bioprinting and clinical science, presenting a major step toward a new approach to treating gastric wall injuries and establishing a proof of concept for the field of bioprinting.

The dental pulp is a soft tissue rich in nerves and blood vessels, which has the function of nutrition, sensation, and defense against various pathogens. In addition, it produces dentin and maintains the biological and physiological viability of dentin.^{134,135} Pulpitis is one of the most common diseases related to the dental pulp and is usually caused by caries and trauma. Some studies have shown that periodontal disease is also associated with a variety of systemic diseases, including diabetes, cardiovascular disease, neurodegenerative diseases, and cancer.^{136,137} Because traditional root canal therapy cannot regenerate pulp tissue,^{138,139} at present, some scholars have performed pulp-dentin regeneration through 3D bioprinting, and many scientific research teams have also achieved some research results in exploring bioinks suitable for tooth regeneration, mainly including fibrin, collagen, sodium alginate, gelatin, GelMA, and some new bioinks.^{140,141} Duarte Campos *et al.*¹⁴² designed a handheld-based *in situ* bioprinting strategy that ultimately enabled angiogenesis within the root canal using collagen bioinks with appropriate biological properties for bioprinting. Due to the simplicity and convenience of the technique, it is feasible for clinical use.

5. Future and challenges

To date, relevant studies have validated the feasibility and practicality of *in situ* 3D bioprinting technology through animal experiments, and graft constructs made with this technology are anticipated to address the shortage of transplanted tissues and organs while also meeting the specific needs of patients for new tissues and organs designed in real time. However, more research is required for clinical translation. To further validate their biocompatibility, safety, and sterility, as well as to reduce printing parameters that require operator control to ensure printing precision and surgical quality, future development and optimization of bioinks and bioprinters suitable to *in situ* bioprinting are required. In addition, with the development of artificial intelligence technology, surgical robots can obtain the three-dimensional structure of defects and quickly deposit bioink in real-time visual analysis, which greatly shortens the operation time and reduces the pain of patients.^{107,143}

"Four-dimensional bioprinting" has developed recently since 3D bioprinting only takes into account the biological structure's starting state and pays little attention to post-printing dynamics.¹⁴⁴ The fourth dimension in 4D bioprinting is time, which stresses the capability of printing multiple materials with time or the creation of a customized-material system that can transform from one shape to another. A more comprehensive definition of 4D printing is that a 3D-printed structure is exposed to a predetermined stimulus (*e.g.*,

temperature, water, light, pH, *etc.*), and its function, shape, and properties can change over time.^{145,146} Excitingly, stimulus-responsive bioinks—which undergo conformational changes under specific trigger conditions (*e.g.*, temperature, pH, humidity, electric current, magnetic field, light, acoustics, or a combination of these stimuli) and may reproduce the natural morphological and structural changes of tissues—show great potential in 4D bioprinting.¹⁴⁷

Bioprinting technology has been rapidly maturing over the past 20 years of development. We believe that the biggest bottleneck to further development is insufficient research on the development process of tissues and organs, making it difficult to print structures with both the desired appearance and functions. Moreover, ethical and clinical regulatory issues pose significant obstacles, as the production of *in vivo* tissues/organs may lead to biosafety and liability issues, and regulators are unsure of how to respond to the potentially uncertain risks (*e.g.*, immune reactions) of this technology.

6. Conclusion

In conclusion, as an emerging tissue engineering technology, *in situ* printing technology can simplify surgical procedures and reduce the dependence of surgical outcomes on the surgeon's skill level, thereby reducing postoperative complications and achieving early recovery. Although some studies have verified the feasibility and practicability of *in situ* 3D bioprinting technology at the level of animal experiments, *in situ* bioprinting still requires more improvement and validation. Before the clinical adoption of *in situ* bioprinting, major breakthroughs need to be made in bioink, printing accuracy, and other aspects of the procedure. However, we believe that the advantages of *in situ* bioprinting make it an important development direction for bioprinting.

Author contributions

Conceptualization, Peige Wang and Jianan Ren; writing—original draft preparation, Ruoqing Li and Yeying Zhao; writing—review and editing, Ruoqing Li, Zhiqiang Zheng and Shurui Song; drafting, Ruoqing Li, Yangyang Liu and Lei Song; project administration, Peige Wang and Jing Dong. All authors read and approved the final manuscript.

Conflicts of interest

There is no conflict of interest regarding the publication of this paper.

Acknowledgements

We thank LetPub (<https://www.letpub.com>) for its linguistic assistance during the preparation of this manuscript. And we sincerely thank Li Ze of Nanjing University for his guidance in writing this review. This study is funded by the Taishan Scholar Foundation of Shandong Province (Grant No. 2018092901).



References

- 1 P. Datta, V. Ozbolat, B. Ayan, A. Dhawan and I. T. Ozbolat, *Biotechnol. Bioeng.*, 2017, **114**, 2424–2431.
- 2 A. Zennifer, S. Manivannan, S. Sethuraman, S. G. Kumbar and D. Sundaramurthi, *Biomater Adv.*, 2022, **134**, 112576.
- 3 P. Prabhakaran, T. Palaniyandi, B. Kanagavalli, V. Ram Kumar, R. Hari, V. Sandhiya, G. Baskar, B. K. Rajendran and A. Sivaji, *Acta Histochem.*, 2022, **124**, 151932.
- 4 L. van der Elst, C. F. de Lima, M. G. Kurtoglu, V. N. Koraganji, M. X. Zheng and A. Gumennik, *Adv. Fiber Mater.*, 2021, **3**, 59–75.
- 5 P. Jain, H. Kathuria and N. Dubey, *Biomaterials*, 2022, **287**, 121639.
- 6 N. Ashammakhi, S. Ahadian, I. Pountos, S. K. Hu, N. Tellisi, P. Bandaru, S. Ostrovidov, M. R. Dokmeci and A. Khademhosseini, *Biomed. Microdevices*, 2019, **21**, 42.
- 7 N. Hong, G. H. Yang, J. Lee and G. Kim, *J. Biomed. Mater. Res., Part B*, 2018, **106**, 444–459.
- 8 P. G. Campbell and L. E. Weiss, *Expert Opin. Biol. Ther.*, 2007, **7**, 1123–1127.
- 9 N. A. Elkasaby and A. A. Mahmoud, *AAPS PharmSciTech*, 2019, **20**, 256.
- 10 S. Singh, D. Choudhury, F. Yu, V. Mironov and M. W. Naing, *Acta Biomater.*, 2020, **101**, 14–25.
- 11 G. Ying, J. Manríquez, D. Wu, J. Zhang, N. Jiang, S. Maharjan, D. H. Hernández Medina and Y. S. Zhang, *Mater. Today Bio*, 2020, **8**, 100074.
- 12 M. Albouy, A. Desanlis, S. Brosset, C. Auxenfans, E. J. Courtial, K. Eli, S. Cambron, J. Palmer, L. Vidal, A. Thépot, M. Dos Santos and C. A. Marquette, *Plast. Reconstr. Surg. Glob. Open*, 2022, **10**, e4056.
- 13 Y. Wu, D. J. Ravnic and I. T. Ozbolat, *Trends Biotechnol.*, 2020, **38**, 594–605.
- 14 K. K. Moncal, R. S. Tigly Aydın, K. P. Godzik, T. M. Aciri, D. N. Heo, E. Rizk, H. Wee, G. S. Lewis, A. K. Salem and I. T. Ozbolat, *Biomaterials*, 2022, **281**, 121333.
- 15 J. Groll, J. A. Burdick, D. W. Cho, B. Derby, M. Gelinsky, S. C. Heilshorn, T. Jüngst, J. Malda, V. A. Mironov, K. Nakayama, A. Ovsianikov, W. Sun, S. Takeuchi, J. J. Yoo and T. B. F. Woodfield, *Biofabrication*, 2018, **11**, 013001.
- 16 S. Heid and A. R. Boccaccini, *Acta Biomater.*, 2020, **113**, 1–22.
- 17 J. Malda, J. Visser, F. P. Melchels, T. Jüngst, W. E. Hennink, W. J. Dhert, J. Groll and D. W. Huttmacher, *Adv. Mater.*, 2013, **25**, 5011–5028.
- 18 A. Fatimi, O. V. Okoro, D. Podstawczyk, J. Siminska-Stanny and A. Shavandi, *Gels*, 2022, **8**, 179.
- 19 Y. Jiang, J. Huang, X. Wu, Y. Ren, Z. Li and J. Ren, *Int. J. Biol. Macromol.*, 2020, **149**, 148–157.
- 20 J. Huang, Y. Jiang, Y. Liu, Y. Ren, Z. Xu, Z. Li, Y. Zhao, X. Wu and J. Ren, *Bioact. Mater.*, 2020, **6**, 770–782.
- 21 G. Chen, J. Ren, Y. Deng, X. Wu, J. Huang, G. Wang, Y. Zhao and J. Li, *J. Biomed. Nanotechnol.*, 2017, **13**, 1660–1672.
- 22 C. Ghobril and M. W. Grinstaff, *Chem. Soc. Rev.*, 2015, **44**, 1820–1835.
- 23 J. Huang, Y. Deng, J. Ren, G. Chen, G. Wang, F. Wang and X. Wu, *Carbohydr. Polym.*, 2018, **186**, 54–63.
- 24 Z. Li, C. Wu, Z. Liu, Z. Li, X. Peng, J. Huang, J. Ren and P. Wang, *RSC Adv.*, 2020, **10**, 1331–1340.
- 25 H. Wang, H. Yu, X. Zhou, J. Zhang, H. Zhou, H. Hao, L. Ding, H. Li, Y. Gu, J. Ma, J. Qiu and D. Ma, *Front. Bioeng. Biotechnol.*, 2022, **10**, 905438.
- 26 Y. J. Chen, X. T. Dong, M. Shafiq, G. Myles, N. Radacs and X. M. Mo, *Adv. Fiber Mater.*, 2022, **4**, 959–986.
- 27 C. B. Highley, C. B. Rodell and J. A. Burdick, *Adv. Mater.*, 2015, **27**, 5075–5079.
- 28 H. Hong, Y. B. Seo, D. Y. Kim, J. S. Lee, Y. J. Lee, H. Lee, O. Ajiteru, M. T. Sultan, O. J. Lee, S. H. Kim and C. H. Park, *Biomaterials*, 2020, **232**, 119679.
- 29 S. Ostrovidov, S. Salehi, M. Costantini, K. Suthiwanich, M. Ebrahimi, R. B. Sadeghian, T. Fujie, X. Shi, S. Cannata, C. Gargioli, A. Tamayol, M. R. Dokmeci, G. Orive, W. Swieszkowski and A. Khademhosseini, *Small*, 2019, **15**, e1805530.
- 30 N. Chen, K. Zhu, Y. S. Zhang, S. Yan, T. Pan, M. Abudupataer, G. Yu, M. F. Alam, L. Wang, X. Sun, Y. Yu, C. Wang and W. Zhang, *ACS Appl. Mater. Interfaces*, 2019, **11**, 30585–30595.
- 31 B. S. Kim, Y. W. Kwon, J. S. Kong, G. T. Park, G. Gao, W. Han, M. B. Kim, H. Lee, J. H. Kim and D. W. Cho, *Biomaterials*, 2018, **168**, 38–53.
- 32 J. Liu, M. Shahriar, H. Xu and C. Xu, *Biofabrication*, 2022, **14**.
- 33 M. Samandari, A. Mostafavi, J. Quint, A. Memić and A. Tamayol, *Trends Biotechnol.*, 2022, **40**, 1229–1247.
- 34 M. Xie, Y. Shi, C. Zhang, M. Ge, J. Zhang, Z. Chen, J. Fu, Z. Xie and Y. He, *Nat. Commun.*, 2022, **13**, 3597.
- 35 M. Hospodiuk, M. Dey, D. Sosnoski and I. T. Ozbolat, *Biotechnol. Adv.*, 2017, **35**, 217–239.
- 36 M. Samandari, J. Quint, A. Rodríguez-de-laRosa, I. Sinha, O. Pourquié and A. Tamayol, *Adv. Mater.*, 2022, **34**, e2105883.
- 37 P. S. Gungor-Ozkerim, I. Inci, Y. S. Zhang, A. Khademhosseini and M. R. Dokmeci, *Biomater. Sci.*, 2018, **6**, 915–946.
- 38 R. Galante, T. J. A. Pinto, R. Colaço and A. P. Serro, *J. Biomed. Mater. Res., Part B*, 2018, **106**, 2472–2492.
- 39 M. Di Foggia, U. Corda, E. Plescia, P. Taddei and A. Torreggiani, *J. Mater. Sci.: Mater. Med.*, 2010, **21**, 1789–1797.
- 40 Z. Dai, J. Ronholm, Y. Tian, B. Sethi and X. Cao, *J. Tissue Eng.*, 2016, **7**, DOI: [10.1177/20417314166648](https://doi.org/10.1177/20417314166648).
- 41 J. R. Dias, N. Ribeiro, S. Baptista-Silva, A. R. Costa-Pinto, N. Alves and A. L. Oliveira, *Front. Bioeng. Biotechnol.*, 2020, **8**, 85.
- 42 L. Vidal, C. Kamplaitner, M. Brennan, A. Hoornaert and P. Layrolle, *Front. Bioeng. Biotechnol.*, 2020, **8**, 61.
- 43 V. Keriquel, H. Oliveira, M. Rémy, S. Ziane, S. Delmond, B. Rousseau, S. Rey, S. Catros, J. Amédée, F. Guillemot and J. C. Fricain, *Sci. Rep.*, 2017, **7**, 1778.
- 44 Y. Chen, J. Zhang, X. Liu, S. Wang, J. Tao, Y. Huang, W. Wu, Y. Li, K. Zhou, X. Wei, S. Chen, X. Li, X. Xu, L. Cardon, Z. Qian and M. Gou, *Sci. Adv.*, 2020, **6**, eaba7406.



- 45 S. Ji and M. Guvendiren, *APL Bioeng.*, 2021, **5**, 011508.
- 46 E. A. Aisenbrey, A. Tomaschke, E. Kleinjan, A. Muralidharan, C. Pascual-Garrido, R. R. McLeod, V. L. Ferguson and S. J. Bryant, *Macromol. Biosci.*, 2018, **18**, DOI: [10.1002/mabi.201700267](https://doi.org/10.1002/mabi.201700267).
- 47 S. Duchi, C. Onofrillo, C. D. O'Connell, R. Blanchard, C. Augustine, A. F. Quigley, R. M. I. Kapsa, P. Pivonka, G. Wallace, C. Di Bella and P. F. M. Choong, *Sci. Rep.*, 2017, **7**, 5837.
- 48 F. Agostinacchio, X. Mu, S. Dirè, A. Motta and D. L. Kaplan, *Trends Biotechnol.*, 2021, **39**, 719–730.
- 49 Z. Emami, M. Ehsani, M. Zandi and R. Foudazi, *Carbohydr. Polym.*, 2018, **198**, 509–517.
- 50 J. Lee, J. Hong, W. Kim and G. H. Kim, *Carbohydr. Polym.*, 2020, **250**, 116914.
- 51 S. D. Kim, S. Jin, S. Kim, D. Son and M. Shin, *Polymers*, 2022, **14**.
- 52 P. R. Cao, L. M. Tao, J. H. Gong, T. M. Wang, Q. H. Wang, J. P. Ju and Y. M. Zhang, *ACS Appl. Polym. Mater.*, 2021, **3**, 6167–6175.
- 53 N. Hakimi, R. Cheng, L. Leng, M. Sotoudehfar, P. Q. Ba, N. Bakhtyar, S. Amini-Nik, M. G. Jeschke and A. Günther, *Lab Chip*, 2018, **18**, 1440–1451.
- 54 X. Wang, C. Yang, Y. Yu and Y. Zhao, *Research*, 2022, **2022**, 9794745.
- 55 S. Ricard-Blum, *Cold Spring Harb. Perspect. Biol.*, 2011, **3**, a004978.
- 56 J. Stepanovska, M. Otahal, K. Hanzalek, M. Supova and R. Matejka, *Gels*, 2021, **7**, 252.
- 57 V. A. Kumar, N. L. Taylor, A. A. Jalan, L. K. Hwang, B. K. Wang and J. D. Hartgerink, *Biomacromolecules*, 2014, **15**, 1484–1490.
- 58 X. Yang, Z. Lu, H. Wu, W. Li, L. Zheng and J. Zhao, *Mater. Sci. Eng. C*, 2018, **83**, 195–201.
- 59 S. Liu, D. Huang, Y. Hu, J. Zhang, B. Chen, H. Zhang, X. Dong, R. Tong, Y. Li and W. Zhou, *RSC Adv.*, 2020, **10**, 39241–39250.
- 60 A. C. Heidenreich, M. Perez-Recalde, A. G. Wusener and E. B. Hermida, *Polym. Test.*, 2020, **82**, 9.
- 61 M. Sun, X. Sun, Z. Wang, S. Guo, G. Yu and H. Yang, *Polymers*, 2018, **10**, 1290.
- 62 X. Wang, Q. Ao, X. Tian, J. Fan, H. Tong, W. Hou and S. Bai, *Polymers*, 2017, **9**, 401.
- 63 J. Berg, T. Hiller, M. S. Kissner, T. H. Qazi, G. N. Duda, A. C. Hocke, S. Hippenstiel, L. Elomaa, M. Weinhart, C. Fahrenson and J. Kurreck, *Sci. Rep.*, 2018, **8**, 13877.
- 64 M. S. Kang, J. I. Kang, P. Le Thi, K. M. Park, S. W. Hong, Y. S. Choi, D. W. Han and K. D. Park, *ACS Macro Lett.*, 2021, **10**, 426–432.
- 65 F. B. Albrecht, F. F. Schmidt, A. C. Volz and P. J. Kluger, *Gels*, 2022, **8**, 611.
- 66 S. Z. Zou, S. N. Fan, A. L. Oliveira, X. Yao, Y. P. Zhang and H. L. Shao, *Adv. Fiber Mater.*, 2022, **4**, 758–773.
- 67 S. Young, M. Wong, Y. Tabata and A. G. Mikos, *J. Control Release*, 2005, **109**, 256–274.
- 68 A. I. Van Den Bulcke, B. Bogdanov, N. De Rooze, E. H. Schacht, M. Cornelissen and H. Berghmans, *Biomacromolecules*, 2000, **1**, 31–38.
- 69 H. Strateffeffen, M. Köpf, F. Kreimendahl, A. Blaeser, S. Jockenhoewel and H. Fischer, *Biofabrication*, 2017, **9**, 045002.
- 70 C. McBeth, J. Lauer, M. Ottersbach, J. Campbell, A. Sharon and A. F. Sauer-Budge, *Biofabrication*, 2017, **9**, 015009.
- 71 K. Ma, T. Zhao, L. Yang, P. Wang, J. Jin, H. Teng, D. Xia, L. Zhu, L. Li, Q. Jiang and X. Wang, *J. Adv. Res.*, 2020, **23**, 123–132.
- 72 P. E. Ludwig, T. J. Huff and J. M. Zuniga, *J. Tissue Eng.*, 2018, **9**, DOI: [10.1177/2041731418769863](https://doi.org/10.1177/2041731418769863).
- 73 C. Colosi, S. R. Shin, V. Manoharan, S. Massa, M. Costantini, A. Barbetta, M. R. Dokmeci, M. Dentini and A. Khademhosseini, *Adv. Mater.*, 2016, **28**, 677–684.
- 74 T. Billiet, E. Gevaert, T. De Schryver, M. Cornelissen and P. Dubruel, *Biomaterials*, 2014, **35**, 49–62.
- 75 N. E. Fedorovich, M. H. Oudshoorn, D. van Geemen, W. E. Hennink, J. Alblas and W. J. Dhert, *Biomaterials*, 2009, **30**, 344–353.
- 76 S. Duchi, C. Onofrillo, C. O'Connell, G. G. Wallace, P. Choong and C. Di Bella, *Methods Mol. Biol.*, 2020, **2140**, 145–157.
- 77 H. Cui, W. Zhu, Y. Huang, C. Liu, Z. X. Yu, M. Nowicki, S. Miao, Y. Cheng, X. Zhou, S. J. Lee, Y. Zhou, S. Wang, M. Mohiuddin, K. Horvath and L. G. Zhang, *Biofabrication*, 2019, **12**, 015004.
- 78 M. N. Collins and C. Birkinshaw, *Carbohydr. Polym.*, 2013, **92**, 1262–1279.
- 79 S. H. Park, J. Y. Seo, J. Y. Park, Y. B. Ji, K. Kim, H. S. Choi, S. Choi, J. H. Kim, B. H. Min and M. S. Kim, *NPG Asia Mater.*, 2019, **11**, 16.
- 80 M. D. Godesky and D. I. Shreiber, *Biointerphases*, 2020, **14**, 061005.
- 81 L. V. Thomas, R. Vg and P. D. Nair, *Int. J. Biol. Macromol.*, 2017, **104**, 1925–1935.
- 82 S. D. Aznar-Cervantes, A. Pagan, B. Monteagudo Santesteban and J. L. Cenis, *Sci. Rep.*, 2019, **9**, 6703.
- 83 S. Chameettachal, S. Midha and S. Ghosh, *ACS Biomater. Sci. Eng.*, 2016, **2**, 1450–1463.
- 84 S. Midha, S. Murab and S. Ghosh, *Biomaterials*, 2016, **97**, 133–153.
- 85 S. Chawla, S. Midha, A. Sharma and S. Ghosh, *Adv. Healthc. Mater.*, 2018, **7**, e1701204.
- 86 M. McGill, J. M. Grant and D. L. Kaplan, *Ann. Biomed. Eng.*, 2020, **48**, 1905–1915.
- 87 W. Shi, M. Sun, X. Hu, B. Ren, J. Cheng, C. Li, X. Duan, X. Fu, J. Zhang, H. Chen and Y. Ao, *Adv. Mater.*, 2017, **29**, DOI: [10.1002/adma.201701089](https://doi.org/10.1002/adma.201701089).
- 88 S. H. Kim, Y. K. Yeon, J. M. Lee, J. R. Chao, Y. J. Lee, Y. B. Seo, M. T. Sultan, O. J. Lee, J. S. Lee, S. I. Yoon, I. S. Hong, G. Khang, S. J. Lee, J. J. Yoo and C. H. Park, *Nat. Commun.*, 2018, **9**, 1620.
- 89 Q. Wu, D. Therriault and M. C. Heuzey, *ACS Biomater. Sci. Eng.*, 2018, **4**, 2643–2652.
- 90 Y. Yang, Z. Wang, Y. Xu, J. Xia, Z. Xu, S. Zhu and M. Jin, *Gels*, 2022, **8**, 314.
- 91 Y. Sun, C. Yang, X. Zhu, J. J. Wang, X. Y. Liu, X. P. Yang, X. W. An, J. Liang, H. J. Dong, W. Jiang, C. Chen,



- Z. G. Wang, H. T. Sun, Y. Tu, S. Zhang, F. Chen and X. H. Li, *J. Biomed. Mater. Res. A*, 2019, **107**, 1898–1908.
- 92 Y. Liu, X. Luo, W. Wu, A. Zhang, B. Lu, T. Zhang and M. Kong, *Int. J. Biol. Macromol.*, 2021, **182**, 689–700.
- 93 M. Puertas-Bartolomé, M. K. Włodarczyk-Biegun, A. Del Campo, B. Vázquez-Lasa and J. San Román, *Polymers*, 2020, **12**, 1986.
- 94 S. Zhang, T. Holmes, C. Lockshin and A. Rich, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 3334–3338.
- 95 C. A. Hauser, R. Deng, A. Mishra, Y. Loo, U. Khoe, F. Zhuang, D. W. Cheong, A. Accardo, M. B. Sullivan, C. Riekel, J. Y. Ying and U. A. Hauser, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 1361–1366.
- 96 E. Gazit, *Chem. Soc. Rev.*, 2007, **36**, 1263–1269.
- 97 S. Zhang, *Nat. Biotechnol.*, 2003, **21**, 1171–1178.
- 98 Y. Chau, Y. Luo, A. C. Cheung, Y. Nagai, S. Zhang, J. B. Kobler, S. M. Zeitels and R. Langer, *Biomaterials*, 2008, **29**, 1713–1719.
- 99 Y. Nagai, L. D. Unsworth, S. Koutsopoulos and S. Zhang, *J. Control Release*, 2006, **115**, 18–25.
- 100 E. L. Bakota, Y. Wang, F. R. Danesh and J. D. Hartgerink, *Biomacromolecules*, 2011, **12**, 1651–1657.
- 101 S. Rauf, H. H. Susapto, K. Kahin, S. Alshehri, S. Abdelrahman, J. H. Lam, S. Asad, S. Jadhav, D. Sundaramurthi, X. Gao and C. A. E. Hauser, *J. Mater. Chem. B*, 2021, **9**, 1069–1081.
- 102 Y. Loo and C. A. Hauser, *J. Mater. Chem. B*, 2015, **11**, 014103.
- 103 D. J. Ravnicek, A. N. Leberfinger, S. V. Koduru, M. Hospodiuk, K. K. Moncal, P. Datta, M. Dey, E. Rizk and I. T. Ozbolat, *Ann. Surg.*, 2017, **266**, 48–58.
- 104 Y. Wu, P. Kennedy, N. Bonazza, Y. Yu, A. Dhawan and I. Ozbolat, *Cartilage*, 2021, **12**, 76–92.
- 105 L. Li, F. Yu, J. Shi, S. Shen, H. Teng, J. Yang, X. Wang and Q. Jiang, *Sci. Rep.*, 2017, **7**, 9416.
- 106 Y. L. Park, K. Park and J. M. Cha, *Micromachines*, 2021, **12**, 12.
- 107 L. Li, J. Shi, K. Ma, J. Jin, P. Wang, H. Liang, Y. Cao, X. Wang and Q. Jiang, *J. Adv. Res.*, 2021, **30**, 75–84.
- 108 Y. He, W. Wang, S. Lin, Y. Yang, L. Song, Y. Jing, L. Chen, Z. He, W. Li, A. Xiong, K. W. K. Yeung, Q. Zhao, Y. Jiang, Z. Li, G. Pei and Z. Y. Zhang, *Bioact. Mater.*, 2022, **9**, 491–507.
- 109 V. Keriquel, F. Guillemot, I. Arnault, B. Guillotin, S. Miraux, J. Amédée, J. C. Fricain and S. Catros, *Biofabrication*, 2010, **2**, 014101.
- 110 O. Kérourédan, D. Hakobyan, M. Rémy, S. Ziane, N. Dusserre, J. C. Fricain, S. Delmond, N. B. Thébaud and R. Devillard, *Biofabrication*, 2019, **11**, 045002.
- 111 L. Vidal, M. Brennan, S. Krissian, J. De Lima, A. Hoornaert, P. Rosset, B. H. Fella and P. Layrolle, *Acta Biomater.*, 2020, **114**, 384–394.
- 112 Y. Zhang, C. Wang, L. Fu, S. Ye, M. Wang and Y. Zhou, *Molecules*, 2019, **24**, 1669.
- 113 Q. Feng, J. Xu, K. Zhang, H. Yao, N. Zheng, L. Zheng, J. Wang, K. Wei, X. Xiao, L. Qin and L. Bian, *ACS Cent. Sci.*, 2019, **5**, 440–450.
- 114 T. Shen, Y. Dai, X. Li, S. Xu, Z. Gou and C. Gao, *ACS Biomater. Sci. Eng.*, 2018, **4**, 1942–1953.
- 115 J. H. Galarraga, M. Y. Kwon and J. A. Burdick, *Sci. Rep.*, 2019, **9**, 19987.
- 116 K. S. Lim, F. Abinzano, P. N. Bernal, A. Albillos Sanchez, P. Atienza-Roca, I. A. Otto, Q. C. Peiffer, M. Matsusaki, T. B. F. Woodfield, J. Malda and R. Levato, *Adv. Healthc. Mater.*, 2020, **9**, e1901792.
- 117 A. J. Sophia Fox, A. Bedi and S. A. Rodeo, *Sports Health*, 2009, **1**, 461–468.
- 118 J. Huang, J. Xiong, D. Wang, J. Zhang, L. Yang, S. Sun and Y. Liang, *Gels*, 2021, **7**, 144.
- 119 C. D. O'Connell, C. Di Bella, F. Thompson, C. Augustine, S. Beirne, R. Cornock, C. J. Richards, J. Chung, S. Gambhir, Z. Yue, J. Bourke, B. Zhang, A. Taylor, A. Quigley, R. Kapsa, P. Choong and G. G. Wallace, *Biofabrication*, 2016, **8**, 015019.
- 120 C. Di Bella, S. Duchi, C. D. O'Connell, R. Blanchard, C. Augustine, Z. Yue, F. Thompson, C. Richards, S. Beirne, C. Onofrillo, S. H. Bauquier, S. D. Ryan, P. Pivonka, G. G. Wallace and P. F. Choong, *J. Tissue Eng. Regen. Med.*, 2018, **12**, 611–621.
- 121 C. Onofrillo, S. Duchi, C. D. O'Connell, R. Blanchard, A. J. O'Connor, M. Scott, G. G. Wallace, P. F. M. Choong and C. Di Bella, *Biofabrication*, 2018, **10**, 045006.
- 122 S. Duchi, C. Onofrillo, C. O'Connell, G. G. Wallace, P. Choong and C. Di Bella, *Methods Mol. Biol.*, 2020, **2140**, 145–157.
- 123 Z. Yang, T. Zhao, C. Gao, F. Cao, H. Li, Z. Liao, L. Fu, P. Li, W. Chen, Z. Sun, S. Jiang, Z. Tian, G. Tian, K. Zha, T. Pan, X. Li, X. Sui, Z. Yuan, S. Liu and Q. Guo, *ACS Appl. Mater. Interfaces*, 2021, **13**, 23369–23383.
- 124 D. Chouhan, N. Dey, N. Bhardwaj and B. B. Mandal, *Biomaterials*, 2019, **216**, 119267.
- 125 J. Wu, Z. Xiao, A. Chen, H. He, C. He, X. Shuai, X. Li, S. Chen, Y. Zhang, B. Ren, J. Zheng and J. Xiao, *Acta Biomater.*, 2018, **71**, 293–305.
- 126 C. Zhou, Y. Yang, J. Wang, Q. Wu, Z. Gu, Y. Zhou, X. Liu, Y. Yang, H. Tang, Q. Ling, L. Wang and J. Zang, *Nat. Commun.*, 2021, **12**, 5072.
- 127 H. Li, F. Cheng, D. P. Orgill, J. Yao and Y. S. Zhang, *Essays Biochem.*, 2021, **65**, 533–543.
- 128 M. Varkey, D. O. Visscher, P. P. M. van Zuijlen, A. Atala and J. J. Yoo, *Burns Trauma*, 2019, **7**, 4.
- 129 J. Gopinathan and I. Noh, *Biomater. Res.*, 2018, **22**, 11.
- 130 A. Parak, P. Pradeep, L. C. du Toit, P. Kumar, Y. E. Choonara and V. Pillay, *Drug Discov. Today*, 2019, **24**, 198–205.
- 131 M. Albanna, K. W. Binder, S. V. Murphy, J. Kim, S. A. Qasem, W. Zhao, J. Tan, I. B. El-Amin, D. D. Dice, J. Marco, J. Green, T. Xu, A. Skardal, J. H. Holmes, J. D. Jackson, A. Atala and J. J. Yoo, *Sci. Rep.*, 2019, **9**, 1856.
- 132 M. Zhao, J. Wang, J. Zhang, J. Huang, L. Luo, Y. Yang, K. Shen, T. Jiao, Y. Jia, W. Lian, J. Li, Y. Wang, Q. Lian and D. Hu, *Mater. Today Bio*, 2022, **16**, 100334.
- 133 W. Zhao and T. Xu, *Biofabrication*, 2020, **12**, 045020.
- 134 K. M. Galler, M. Weber, Y. Korkmaz, M. Widbiller and M. Feuerer, *Int. J. Mol. Sci.*, 2021, **22**.
- 135 Y. C. Bae and A. Yoshida, *J. Oral Sci.*, 2020, **62**, 126–130.



Review

- 136 G. Hajishengallis and T. Chavakis, *Nat. Rev. Immunol.*, 2021, **21**, 426–440.
- 137 P. M. Preshaw and S. M. Bissett, *Br. Dent. J.*, 2019, **227**, 577–584.
- 138 T. Connert, R. Weiger and G. Krastl, *Int. Endod. J.*, 2022, **55**, 995–1002.
- 139 Z. Xie, Z. Shen, P. Zhan, J. Yang, Q. Huang, S. Huang, L. Chen and Z. Lin, *Int. J. Mol. Sci.*, 2021, **22**.
- 140 J. Han, D. S. Kim, H. Jang, H. R. Kim and H. W. Kang, *J. Tissue Eng.*, 2019, **10**, DOI: [10.1177/2041731419845849](https://doi.org/10.1177/2041731419845849).
- 141 H. Yu, X. Zhang, W. Song, T. Pan, H. Wang, T. Ning, Q. Wei, H. H. K. Xu, B. Wu and D. Ma, *J. Endod.*, 2019, **45**, 706–715.
- 142 D. F. Duarte Campos, S. Zhang, F. Kreimendahl, M. Köpf, H. Fischer, M. Vogt, A. Blaeser, C. Apel and M. Esteves-Oliveira, *Connect Tissue Res.*, 2020, **61**, 205–215.
- 143 J. Lipskas, K. Deep and W. Yao, *Sci. Rep.*, 2019, **9**, 3746.
- 144 G. Qu, J. Huang, Z. Li, Y. Jiang, Y. Liu, K. Chen, Z. Xu, Y. Zhao, G. Gu, X. Wu and J. Ren, *Mater. Today Bio*, 2022, **16**, 100363.
- 145 B. Gao, Q. Yang, X. Zhao, G. Jin, Y. Ma and F. Xu, *Trends Biotechnol.*, 2016, **34**, 746–756.
- 146 Q. Yang, B. Gao and F. Xu, *Biotechnol. J.*, 2020, **15**, e1900086.
- 147 N. Ashammakhi, S. Ahadian, F. Zengjie, K. Suthiwanich, F. Lorestani, G. Orive, S. Ostrovidov and A. Khademhosseini, *Biotechnol. J.*, 2018, **13**, e1800148.

